

New, first in class target receptor for Platform therapy of GI Cancers

YB-800 was discovered through scouting in 2022 with the specific intent to develop new, first in class drugs for hard to treat cancers and improve standard of care.


PROBLEM STATEMENT – Lead Indication: Gastric Cancer



YB-800 – THE PLATFORM


- ADC Candidate YB-800ADC:** indications in **GI and Breast cancer**.
- Bi-Specific Candidate YB-800BS1 and YB-800BS2:** indications in **solid tumors**.
- Radio-labeled Candidate YB-800R1:** indications in **solid tumors**
- Radio-labeled Candidate YB-800R2:** **diagnostic tool** to identify primary tumor and its metastases

GASTRIC CANCER – CURRENT TREATMENTS, INCIDENCE AND MARKET FORECAST



¹: NCCN treatment guidelines; ²: ~15% of patients; ³: ~5% of patients ⁴: Globocan 2020; ⁵: <https://www.alliedmarketresearch.com/gastric-cancer-market-A74458>

DEVELOPMENT TIMELINES



INTELLECTUAL PROPERTY

YB-800 Patent in country phase at the moment, i.e. EP, CHN & JPN
 Patent granted in the US: 03. October 2023
 Filing date YB-800: 25 JAN 2019

ACCOMPLISHMENTS

- Owner of Patent; no license fees
- Fully humanized monoclonal antibody
- Established internalization results in vitro
- ASCO abstract submitted
- Selection of YB-800 as lead asset

LEAD ASSET & TARGETS

YB-800 first-in-class antibody, binding to new receptor target present on GI tumors. Healthy tissue not affected.

Wide applicability due to presence in the following cancers:

- Colorectal Cancer
- Gastric Cancer
- Esophageal Cancer
- Hepatocellular Carcinoma
- Pancreatic Cancer
- Bladder Cancer
- Breast Cancer
- Thyroid Cancer

Occurrence of New Target Receptor in GI Cancers: on average **50% of patients** express this New Target Receptor

MARKET SIZE IN 2031

Gastric Cancer – possible first line challenge - **\$10.7B total**

MANAGEMENT TEAM

- Peter Schiemann | PhD,**
 CEO & Chairman of the Board
 Co-founder & entrepreneur with over 30 years experience in Pharma
- Angela Gibbs | MBA, CBO**
 Over 25 years experience in Business Development
- Michel Janicot | PhD, CDO**
 Over 30 years experience in Drug Development and Preclinical Oncology
- Christian Germa | MBA, CFO**
 Over 25 years experience in Finance

ADVISORY TEAM & BOARD MEMBERS

- Katrin Rupalla | PhD, MBA**
 Co-founder & Drug Development Expert in Oncology; Global Head Regulatory @ J&J
- Prof. Lopa Mishra | MD**
 Scientific Advisor
 Expert in GI cancer treatment; Commitment for Ph I study
- Prof. Gunther Wennemuth | MD**
 Scientific Advisor
 Expert in Immunohistochemistry and pathology
- Prof. Mitsuro Kanda | MD**
 Scientific Advisor and YB-800 inventor
 Surgeon for GI cancers, specialization on Gastric and Esophageal Cancer

Juergen Heitmann | PhD

NED
 Experienced BD Expert with experience in Pharma, VC and start-up companies

Caroline Germa | MD

NED
 Physician with over 25 year of experience in oncology drug development